phrykt

Vanda Pharmaceuticals Inc. (VNDA): who owns it and who trades it

As of Nov 16, 2026, VNDA insiders reported 6 open-market sales worth $2.8M and 3 purchases worth $38.1K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mihael Hristos Polymeropoulos (CEO), with $1.3M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Vanda Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns VNDA

170 funds and institutions reported VNDA shares worth $308M at the end of Q2 2026, about 84% of the company. The largest holder is BlackRock, Inc. with 12.7%.

Funds and institutions (13F) 84%Everyone else 16%

10 largest owners, by share of the company

BlackRock, Inc.12.7%
State Street Corp5.8%
AQR Capital Management LLC5.8%
Renaissance Technologies LLC5.7%
Vanguard Capital Management LLC4.2%
AIGH Capital Management LLC3.4%
Acadian Asset Management LLC3.2%
Dimensional Fund Advisors LP2.9%
Millennium Management LLC2.7%
Geode Capital Management, LLC2.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.7.65M12.73%$46.8M+5%
State Street Corp3.52M5.85%$21.5M+17%
AQR Capital Management LLC3.50M5.82%$21.4M+118%
Renaissance Technologies LLC3.44M5.72%$21.1M-8%
Vanguard Capital Management LLC2.52M4.20%$15.4M+2%
AIGH Capital Management LLC2.04M3.40%$12.5M-26%
Acadian Asset Management LLC1.92M3.19%$11.7M+7%
Dimensional Fund Advisors LP1.73M2.87%$10.6M-2%
Millennium Management LLC1.60M2.67%$9.8M-15%
Geode Capital Management, LLC1.48M2.47%$9.1M+3%
Two Sigma Investments, LP1.35M2.24%$8.3M-4%
Marshall Wace, LLP1.23M2.04%$7.5M+106%
Jacobs Levy Equity Management, Inc1.21M2.02%$7.4M+4%
Krensavage Asset Management, LLC1.18M1.96%$7.2MNo change
Vanguard Portfolio Management LLC1.13M1.88%$6.9M+11%
Goldman Sachs Group Inc1.04M1.72%$6.3M+24%
Citadel Advisors LLC758,3021.26%$4.6M+20%
Qube Research & Technologies Ltd729,2121.21%$4.5M–
Federated Hermes, Inc.714,2781.19%$4.4M+24%
Charles Schwab Investment Management Inc646,2561.07%$4M+17%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, VNDA insiders reported $38.1K of open-market purchases and $2.8M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$38.1K
3 trades, 1 people
Sales, 12 months
$2.8M
6 trades, 6 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 5, 2026
Filed Nov 5, 2026

Purchases and sales by month

$2.6M$2.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 5, 2026Charles Cliff DuncanDirectorPurchase5,803$3.80$22.1KForm 4
Nov 4, 2026Charles Cliff DuncanDirectorPurchase3,447$3.82$13.2KForm 4
Nov 3, 2026Charles Cliff DuncanDirectorPurchase750$3.80$2.8KForm 4
Mar 2, 2026Timothy WilliamsVice presidentSale42,434$8.27$351KForm 4
Mar 2, 2026Kevin Patrick MoranCFOSale42,442$8.27$351KForm 4
Mar 2, 2026Joakim WijkstromVice presidentSale30,800$8.27$255KForm 4
Mar 2, 2026Mihael Hristos PolymeropoulosCEOSale156,235$8.17$1.3MForm 4
Mar 2, 2026Gunther BirznieksVice presidentSale42,431$8.27$351KForm 4
Feb 23, 2026Tage HonoreDirectorSale30,000$8.03$241KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Mihael Hristos PolymeropoulosPresident and CEO, Director–$1.3MMar 2, 2026
Kevin Patrick MoranSVP, CFO & Treasurer–$351KMar 2, 2026
Timothy WilliamsSVP & General Counsel–$351KMar 2, 2026
Gunther BirznieksSVP, Business Development–$351KMar 2, 2026
Joakim WijkstromSVP, Chief Marketing Officer–$255KMar 2, 2026
Tage HonoreDirector–$241KFeb 23, 2026
Charles Cliff DuncanDirector$38.1K–Nov 5, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VNDA short interest

High short interest. 12.6% of VNDA shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 20%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 7.62M VNDA shares were sold short, 12.6% of the shares outstanding, down 8.3% from the report before. At the average daily volume of 1.28M shares, buying them all back would take about 5.9 trading days (days to cover).

Shares short, % of all shares

12.6%May 15Oct 3014.6%

Days to cover

5.9May 15Oct 3013.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20267.62M12.61%-8%1.28M5.9
Oct 15, 20268.31M13.74%+6%1.00M8.3
Sep 30, 20267.83M12.95%-8%1.21M6.5
Sep 15, 20268.50M14.05%+11%703,57812.1
Aug 31, 20267.69M12.71%+0%778,7419.9
Aug 14, 20267.67M12.68%+3%1.25M6.2
Jul 31, 20267.42M12.28%+3%824,8759.0
Jul 15, 20267.19M11.95%-2%816,7048.8
Jun 30, 20267.34M12.21%+5%932,6977.9
Jun 15, 20266.99M11.62%+3%898,4607.8
May 29, 20266.81M11.33%+7%1.00M6.8
May 15, 20266.37M10.59%+3%1.30M4.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Vanda Pharmaceuticals company events

Vanda Pharmaceuticals filed 14 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 28, 2026.

  1. Oct 28, 2026ResultsReleased financial results. Filing
  2. Aug 5, 2026ResultsReleased financial results. Filing
  3. Jun 5, 2026VoteReported shareholder vote results. Filing
  4. May 6, 2026ResultsReleased financial results. Filing
  5. Apr 22, 2026LeadershipThe Board of Directors of Vanda Pharmaceuticals Inc. expanded the size of the Board from six to seven members, effective immediately and appointed Charles C. Duncan, Ph.D., as a director of the Company to fill the vacancy created by the expansion. Filing
  6. Apr 2, 2026LeadershipTimothy Williams notified Vanda Pharmaceuticals Inc. of his resignation as the Company’s Senior Vice President, General Counsel and Secretary, effective as of April 10, 2026, in order to pursue other endeavors. Filing
  7. Mar 10, 2026AnnouncementShared information with investors. Filing
  8. Feb 23, 2026AnnouncementVanda Pharmaceuticals Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved Bysanti TM (milsaperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and the treatment of schizophrenia in adults. Filing
  9. Feb 19, 2026LeadershipThe Compensation Committee of the Board of Directors of Vanda Pharmaceuticals Inc. awarded 2025 annual bonuses and approved 2026 annual base salaries and 2026 bonus target amounts for the Company’s named executive officers. Filing
  10. Feb 11, 2026ResultsReleased financial results. Filing
  11. Jan 8, 2026AnnouncementAs previously disclosed, on October 1, 2025, Vanda Pharmaceuticals Inc. announced that it had reached a collaborative framework with the U.S. Food and Drug Administration pursuant to which, among other things, the FDA had agreed to conduct an expedited re-review of Vanda’s supplemental New Drug… Filing
  12. Dec 31, 2025AnnouncementVanda Pharmaceuticals Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved NEREUS TM (tradipitant) for the prevention of vomiting induced by motion. Filing
  13. Dec 4, 2025AnnouncementVanda Pharmaceuticals Inc. issued a press release announcing that the U.S. Food and Drug Administration has lifted the partial clinical hold on Vanda’s drug, tradipitant, for the treatment of motion sickness. Filing
  14. Nov 28, 2025AnnouncementVanda Pharmaceuticals Inc. issued a press release providing a regulatory update on Vanda’s drug, tradipitant, for the treatment of motion sickness. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Vanda Pharmaceuticals financials

Famous investors that hold VNDA

6 of the 50 well-known investors we track reported holding VNDA in their latest 13F filing. The largest position is Israel Englander's, worth $20.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20264.26M$20.9M0.0%+166%
Jim Simons · Renaissance TechnologiesQ3 20263.31M$16.2M0.0%-4%
Steve Cohen · Point72 Asset ManagementQ3 2026102,409$503K0.0%-67%
Ken Griffin · Citadel AdvisorsQ3 202674,039$364K0.0%-90%
Jeremy Grantham · GMOQ3 202621,737$107K0.0%-23%
Paul Tudor Jones · Tudor Investment CorpQ3 202614,402$70.7K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named VNDA in the last 120 days.

FiledHolderFormStake
Nov 13, 2026AQR Capital Management, LLC13G/A3.5%
Nov 13, 2026AQR Capital Management, LLC13G/A3.5%
Nov 10, 2026STATE STREET CORPORATION13G5.0%
Nov 10, 2026STATE STREET CORPORATION13G5.0%
Oct 27, 2026BlackRock Portfolio Management LLC13G5.9%
Oct 27, 2026BlackRock Portfolio Management LLC13G5.9%
Oct 9, 2026Millennium Management LLC13G/A7.0%
Oct 9, 2026Millennium Management LLC13G/A7.0%

Questions about Vanda Pharmaceuticals Inc. (VNDA) stock

Who owns the most VNDA stock?

The largest reported owner of Vanda Pharmaceuticals Inc. (VNDA) is BlackRock, Inc., with 12.7% of the company. In total, 170 funds and institutions reported holding VNDA at the end of Q2 2026, together about 84% of the shares. See the largest owners.

Are VNDA insiders buying or selling?

In the last 12 months, VNDA insiders reported 3 open-market purchases worth $38.1K and 6 sales worth $2.8M. The latest trade was on Nov 5, 2026. See every trade.

What is the short interest in VNDA?

As of Oct 30, 2026, 7.62M VNDA shares were sold short, 12.6% of the shares outstanding, down 8.3% from the report before. At the average daily volume of 1.28M shares, buying them all back would take about 5.9 trading days (days to cover). See the history.

Which famous investors hold VNDA?

6 of the 50 well-known investors we track reported VNDA in their latest 13F filing, including Israel Englander, Jim Simons, Steve Cohen. The largest position is worth $20.9M. See all holders.

Executive pay

Vanda Pharmaceuticals's chief executive was paid a total of $3.9M for the year ended Dec 31, 2025, down 1% from $3.9M the year before. In the last 12 months, Vanda Pharmaceuticals's executives and directors bought $38.1K of stock on the open market and sold $2.8M.

Chief executive, total pay$3.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$7.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.